Development of a vaccine to prevent Japanese encephalitis: a brief review

Viroj Wiwanitkit
Wiwanitkit House, Bangkhae, Bangkok, Thailand

Abstract: Japanese encephalitis (ICD 10: A83.0) is an important specific viral encephalitis caused by the Japanese encephalitis virus, a virus of the Flavivirus group. Millions of people, especially those in endemic areas of developing countries in Asia, are at high risk from this infection. Therefore proper management to deal with this virus is essential. There is no specific treatment for Japanese encephalitis virus. Supportive and symptomatic treatments are usually used, which emphasize the importance of prevention in this specific neurological disorder. Vector control or vaccination can be used to prevent the disease. Because the existing Japanese encephalitis vaccine poses some undesirable problems, a new vaccine is needed. The process of developing a new vaccine is briefly discussed.

Keywords: Japanese encephalitis, vaccine, concept, prevention, development

Introduction to Japanese encephalitis

Acute inflammation of the brain is the hallmark of encephalitis. Encephalitis has several causes, including biological, chemical and physical insults. Infection is an interesting cause of encephalitis. Several infections can lead to encephalitis, among which viral infections are important. Viral encephalitis can be fatal, and usually presents problems for the physician. Many viruses causing encephalitis are documented in the medical literature, among which Japanese encephalitis (ICD 10: A83.0) is important. Japanese encephalitis is a specific neurological disturbance that is caused by Japanese encephalitis virus, which is a member of in the Flavivirus group.

Japanese encephalitis is classified as an important mosquito-borne infection. Mosquito vectors are Culex spp, especially C. gelidus and C. tritaeniorhynchus. These vectors usually live in fields and water reservoirs in rural and suburban areas. The disease can be frequently seen in developing countries in Asia, where suitable breeding sites of the mosquito vectors are abundant. Because of the nature of this vector-borne disease, it remains a focus of public health around the world, especially in tropical regions (Table 1). Because millions of people, especially those in developing countries, are at high risk from this viral infection, proper management of this disease is essential.

Another interesting feature of the transmission cycle of Japanese encephalitis virus is that pigs can harbor the virus and act as an amplifying host. Because the virus can then be further transmitted by mosquitoes to humans, it can be classified as a pig-related disease. The disease is common in many pig-farming areas. A case presenting classical viral encephalitis symptoms with a history of living in a
Table 1 Situation of Japanese encephalitis in different regions of the world

<table>
<thead>
<tr>
<th>Areas</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asia</td>
<td>Tropical Asia is the endemic area of Japanese encephalitis. There are many outbreaks in Asia in each year. South Asia (especially India) and Southeast Asia are the two main regions where Japanese encephalitis is prevalent. Poverty is a big underlying risk factor for Japanese encephalitis in Asia. However, this does not mean that there is no problem for rich countries. Of interest, Japan, from where the name Japanese encephalitis is derived, still has this disease although it is controlled.</td>
</tr>
<tr>
<td>Africa</td>
<td>Although the socioeconomic status is lower than in Asia, the prevalence of disease is nil, because of the geographical pattern of Japanese encephalitis. However, there is confirmed evidence for an intermediate risk of Japanese encephalitis transmission in Africa (compared to high risk for dengue).</td>
</tr>
<tr>
<td>Australia</td>
<td>Japanese encephalitis is a new emerging arbovirus infection in Australia.</td>
</tr>
<tr>
<td>South America</td>
<td>The Americas are currently not at risk of Japanese encephalitis.</td>
</tr>
</tbody>
</table>

Japanese encephalitis is a new emerging arbovirus infection in South America. Any patient presenting with fever and the neurological signs and symptoms should receive a complete assessment for possible viral encephalitis. Briefly, the common symptoms include alteration of consciousness and seizure. An alteration in EEG is also detectable. Encephalitis is the presumptive diagnosis for such cases. However, because the neurological manifestations of Japanese encephalitis are highly similar to those of other kinds of viral encephalitis, simple clinical observation does not easily differentiate between Japanese encephalitis and the other kinds of encephalitis. A laboratory investigation is invariably necessary.

As already mentioned, diagnosing Japanese encephalitis is not easy. The clinical diagnosis requires further verification by standard medical laboratory investigation. Immuno-diagnosis, the basic diagnostic laboratory test, remains the gold standard. However, confirmed diagnosis is usually late in the course of the disease because the patient will usually have full-blown neurological signs and symptoms before the physician in charge becomes aware of the possibility of a diagnosis of Japanese encephalitis. A few commercial

Table 2 Neurological manifestations of Japanese encephalitis

<table>
<thead>
<tr>
<th>Aspects</th>
<th>Descriptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signs and symptoms</td>
<td>Fever (high or low), nausea and vomiting, stupor; alteration of consciousness, loss of consciousness, seizure (generalized or focal).</td>
</tr>
<tr>
<td>Laboratory findings</td>
<td>Cerebrospinal fluid (CSF) profile shows white blood cells about 5–500/mm³ with lymphocyte predominance (however, neutrophilia can be seen in the first 3 days). CSF protein is about 50–200 mg/dL and CSF sugar is not depleted. It should be noted that this is not specific for Japanese encephalitis but a common CSF profile for all viral encephalitis.</td>
</tr>
<tr>
<td>Definite diagnosis</td>
<td>Definite diagnosis is based on immunodiagnosis. Specific Japanese encephalitis IgM (by ELISA) in CSF or serum ≥40 units (in serum, the ratio of Japanese encephalitis/dengue IgM by ELISA must be more than 1). In case of death, definite diagnosis can also be made during autopsy. The main finding is the detection of Japanese encephalitis antigen in the brain tissue.</td>
</tr>
<tr>
<td>EEG</td>
<td>Alteration of EEG pattern can be seen corresponding to the presentation of seizure. According to Misra and Kalita, “Upon comparison of the JE patients with and without seizures, EEG slowing and cortical and thalamic lesion on CT or MRI were significantly related to the occurrence of the seizures; however, it was not associated with poor outcome.”</td>
</tr>
<tr>
<td>Imaging</td>
<td>There is no specific significant finding on CT or MRI. However, as noted by Misra and Kalita, the specific lesion that might be related to the seizure, but not the prognosis, should be kept in mind.</td>
</tr>
</tbody>
</table>
The vaccine has to be refrigerated at 2–8°C. Localized inflammation at injection site can be seen at a rate of about 10%–20% and is most common at first dose.

There are two package forms of Japanese encephalitis vaccine including liquid and lyophilized forms: liquid form as either 1 mL of vaccine consists of 801 µL of effective protein (97% is the antigenic protein of Japanese encephalitis virus), thimerosal (as preservation) and gelatin (as stabilizer).

Package

1 mL/dose (for Nakayama strain) or 0.5 mL/dose (for Beijing strain); lyophilized (freeze-dried form) as 0.5 mL/dose (for Beijing strain). The lyophilized form has a longer shelf life.

Administration

Subcutaneous injection is recommended. For general cases, 1 dose must be injected at the deltoid area. For children aged less than 3 years old, half dosage is recommended for injection at the thigh area.

Schedule

According to the general expanded program for immunization (EPI), vaccination is suggested for children in endemic areas starting at 12 months. The vaccination schedule is on day 0, 1 month and 1 year. For highly endemic areas, a fourth booster dosage is recommended at 5 years. For visitors to endemic areas, pre-exposure vaccination is recommended, at day 0, day 7 and 1 month. A special extra short schedule at day 0, day 7 and day 14 is also acceptable (but offers less protection).

Contraindication

The main contraindications include fever and pregnancy. The relative contraindications are severe heart disease, severe liver disease, severe kidney disease and those with history of vaccine allergy or seizure within previous year.

Adverse effect

Localized inflammation at injection site can be seen at a rate of about 10%–20% and is most common at first dose. Sometimes, fever can be seen owing to the inflammation. Angioedema can also be seen at day 1 to day 3, at about 0.2%–0.6%, and is commonly detected at the second dose. Rarely, neurological complications such as encephalopathy can also be detected. Anaphylaxis due to vaccination is rare.

Storage

The vaccine has to be refrigerated at 2–8°C. The diluted lyophilized vaccine can be kept for 1 day. The shelf life for liquid vaccine is 1 year and the shelf life of lyophilized vaccine is about 3–5 years.

Table 3 Details of classical inactivated mouse brain Japanese encephalitis vaccine

<table>
<thead>
<tr>
<th>Aspects</th>
<th>Descriptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type</td>
<td>This is an inactivated vaccine, derived from controlled infected mouse brain. The inactivation of the virus from infected mouse brain is due to formalin application. After inactivation, the vaccine is further purified. Two main strains are used for production of Japanese encephalitis vaccine: Nakayama and Beijing (the latter strain is the better)</td>
</tr>
<tr>
<td>Composition</td>
<td>1 mL of vaccine consists of 801 µL of effective protein (97% is the antigenic protein of Japanese encephalitis virus), thimerosal (as preservation) and gelatin (as stabilizer)</td>
</tr>
<tr>
<td>Package</td>
<td>There are two package forms of Japanese encephalitis vaccine including liquid and lyophilized forms: liquid form as either 1 mL/dose (for Nakayama strain) or 0.5 mL/dose (for Beijing strain); lyophilized (freeze-dried form) as 0.5 mL/dose (for Beijing strain). The lyophilized form has a longer shelf life.</td>
</tr>
<tr>
<td>Administration</td>
<td>Subcutaneous injection is recommended. For general cases, 1 dose must be injected at the deltoid area. For children aged less than 3 years old, half dosage is recommended for injection at the thigh area.</td>
</tr>
<tr>
<td>Schedule</td>
<td>According to the general expanded program for immunization (EPI), vaccination is suggested for children in endemic areas starting at 12 months. The vaccination schedule is on day 0, 1 month and 1 year. For highly endemic areas, a fourth booster dosage is recommended at 5 years. For visitors to endemic areas, pre-exposure vaccination is recommended, at day 0, day 7 and 1 month. A special extra short schedule at day 0, day 7 and day 14 is also acceptable (but offers less protection).</td>
</tr>
<tr>
<td>Contraindication</td>
<td>The main contraindications include fever and pregnancy. The relative contraindications are severe heart disease, severe liver disease, severe kidney disease and those with history of vaccine allergy or seizure within previous year.</td>
</tr>
<tr>
<td>Adverse effect</td>
<td>Localized inflammation at injection site can be seen at a rate of about 10%–20% and is most common at first dose. Sometimes, fever can be seen owing to the inflammation. Angioedema can also be seen at day 1 to day 3, at about 0.2%–0.6%, and is commonly detected at the second dose. Rarely, neurological complications such as encephalopathy can also be detected. Anaphylaxis due to vaccination is rare.</td>
</tr>
<tr>
<td>Storage</td>
<td>The vaccine has to be refrigerated at 2–8°C. The diluted lyophilized vaccine can be kept for 1 day. The shelf life for liquid vaccine is 1 year and the shelf life of lyophilized vaccine is about 3–5 years.</td>
</tr>
</tbody>
</table>

kits for detecting Japanese encephalitis are available. In addition, as a vector-borne disease of poor, developing countries, pharmaceutical companies in the developed world have little interest in the disease.

As member of the Flavivirus group, there is no specific treatment. All cases need supportive and symptomatic treatment in hospital, which emphasizes the importance of prevention. Intravenous fluid (usually 5% dextrose half strength saline solution) administration at maintenance dosage is recommended. Seizures can be treated with an anticonvulsive drug such as phenytoin and phenobarbital.

Vaccination

Prevention can be by either vector control or vaccination. Mosquito control is difficult because of their sheer numbers. Preventing mosquito bites will be more effective than mosquito control, but this is also sometimes very difficult. Vaccination seems to be the most effective alternative preventive. Japanese encephalitis vaccine is available and used in many countries. In clinical practice, the inactivated mouse brain Japanese encephalitis vaccine (BIKEN/JEVAX vaccine) is widely used. Other vaccines are also used in some parts of the world, including the dead Nakayama strain vaccine used in parts of China and the live SA14-14-2 vaccine used in China and some Asian countries, including Thailand.

A three-dosage vaccination schedule is recommended to achieve full immunity in endemic areas in which the virus is endemic. It has been proved that 80% immunogenicity can be achieved after the second vaccination and the generated immunity can last for 1 year. If the third vaccination is completed, immunogenicity can reach 100% and the

Table 4 Some important problems of presently used Japanese encephalitis vaccine

<table>
<thead>
<tr>
<th>Problems</th>
<th>Causes</th>
<th>Possible correction</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Induction of unwanted adverse neurological reactions</td>
<td>the nature of mouse brain-derived vaccine</td>
<td>cell culture-based or recombinant vaccine by advanced biotechnology</td>
</tr>
<tr>
<td>2. Loss of follow-up for the third vaccination</td>
<td>long interval in the present vaccination schedule</td>
<td>new single-dose vaccination</td>
</tr>
<tr>
<td>3. Expensive</td>
<td>few manufacturers, nature of the disease, which is common in poor countries</td>
<td>promotion of equity in drug and vaccine trade</td>
</tr>
</tbody>
</table>
generated immunity can last for at least 5 years.\textsuperscript{42–45} However, the risk of excessive repeated booster vaccinations has been noted in the medical literature.

**Problems with the current vaccine**

The presently used vaccine is derived from mouse brain and can induce unwanted adverse neurological effects. This is the main reason for the need to find a new vaccine. A vaccine based on cell culture or recombinant technology has the potential to reduce unwanted adverse neurological effects.\textsuperscript{49,50}

**Problems with vaccination**

The presently used vaccination schedule, a three-dosage regimen over a year-long period, poses the problem of loss of follow-up, especially for the third dosage, resulting in an unsuccessful vaccination program. A single-dosage vaccine would overcome this disadvantage, and is the target of new vaccine development. Recently, a new Japanese encephalitis vaccine has been produced. The Japanese encephalitis vaccine IC-51, known as IXIARO, is the newest inactivated virus (strain SA(14)-14-2), which is manufactured in cultured Vero cells and needs only two doses in a vaccination program.\textsuperscript{51,52} thus solving the problem of a too-long vaccination program.

**Problems with vaccines**

In certain situations, some specific vaccines cannot be used, for example, in the pregnant. This presents a challenge for vaccinologists.

Affordability in developing countries can limit the effectiveness of vaccines. Although Japanese encephalitis vaccination is included in the national policy of some countries, high cost can still be a barrier. Japanese encephalitis is a disease of the poor and has received very little attention in wealthy countries except Japan.

**Finding a new vaccine for Japanese encephalitis**

Because of the problems discussed above, a new vaccine for Japanese encephalitis is needed.\textsuperscript{53–55} A new vaccine must be more effective, safer and of higher immunogenicity, and without the problems of the presently used vaccine, ie, adverse neurological effects and a long vaccination schedule.

Finding a new epitope is usually the first step in finding a new vaccine. The focus can be the immunogenic protein already used in vaccine production. Despite the protein’s availability, it is still difficult to find a new epitope. It is a time-consuming process if based on classical techniques. Immunomics,\textsuperscript{56–59} a new branch of bioinformatics, can be useful for this purpose. Since Japanese encephalitis is a viral infection, the favorable epitope should be a specific T cell epitope which has an important role in immunogenicity via the T cell immune system. Alternative T cell epitopes can be useful in developing a multi-epitope vaccine.

Once the desired epitopes have been found, a new vaccine can be developed. Basically, because the vaccine is usually a peptide, advanced protein technology can be helpful in vaccine production. The new Japanese encephalitis vaccine should be a cell culture-based vaccine or a recombinant protein-based vaccine. The use of current genetic recombination technology can help produce the desired peptide in large amounts in a short time. This process also guarantees the purity of the new peptide, which would eliminate the problem of adverse neurological effects with classical Japanese encephalitis vaccine.

The next step in the process is testing the new vaccine’s properties. Although they can be predicted from the vaccine’s expression of visible action or function through silico gene expression technology, classical in vitro and in vivo testing are still needed to confirm the vaccine’s efficacy and safety.\textsuperscript{60–65} Several new new peptides have been discovered within the past few years, based on cell culture, recombinant technology or DNA technology, and their effectiveness is being trialed.\textsuperscript{60–65}

The newest vaccine, IXIARO, was also developed by a cell culture technique. Its safety and efficacy have been confirmed, it is newly licensed in both Europe and the US, and is now poised to be licensed in many Asian countries.\textsuperscript{51,52} Combined vaccines containing a specific vaccine for other viruses are also the focus of current developmental research on Japanese encephalitis vaccine.\textsuperscript{66,67} ChimeriVax-JE, a chimeric live attenuated vaccine using yellow fever (YF) 17D vaccine as a vector, is the best example.\textsuperscript{68,69} ChimeriVax-JE is accepted as a cost-effective prophylactic vaccine for Japanese encephalitis and can provide protective levels of neutralizing antibody after a single dose.\textsuperscript{70} ChimeriVax-JE can also protect against other viruses belonging to the Japanese encephalitis virus serocomplex.\textsuperscript{71} ChimeriVax-JE vaccine is licensed in some countries, for example, Thailand, China and India.

If the results from classical trials on a new vaccine are favorable, it will be launched on the market after passing the regulatory and registration processes of each country. Finally, post-marketing surveillance, similar to that for any new drug
or vaccine, will still be required to complete the process of finding a new vaccine for Japanese encephalitis.

**Disclosure**
The author discloses no conflicts of interest.

**References**


